LEGNLegend Biotech Corporation
What is the market doing?
No clear lean: nothing decisive, though in a downtrend (−16% vs 200-day).
In a downtrend, below its 50- and 200-day averages. Price is −16% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Moderately shorted, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How LEGN is trading
Legend Biotech Corporation is −45% over the past year while the S&P 500 is +18%: 64 points behind the market.
1-year return · S&P 500 +18%
- vs 200-day average
- −16%
vs 200-day average · a clear downtrend
- RSI (14)
- 51
RSI (14) · neutral
- Below its 52-week high
- 49%
Below its 52-week high
Details›
- Last close2026-10-09
- $18.62
- 1 monthS&P 500 +2.7%
- −3.0%
- 1 yearS&P 500 +18%
- −45%
- 5 yearsS&P 500 +88%
- −51%
- vs 50-day average$19.74
- −5.7%
- 52-week high
- $36.28
- 52-week low
- $16.65
- Annualised volatility
- 63%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- −$480K
| Year | Return |
|---|---|
| 2026 (year to date) | −14% |
| 2025 | −33% |
| 2024 | −46% |
| 2023 | +21% |
| 2022 | +7.1% |
| 2021 | +66% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 6 | 2 of 6 | −4.8% |
| Feb | 6 | 3 of 6 | +1.8% |
| Mar | 6 | 2 of 6 | −3.1% |
| Apr | 6 | 5 of 6 | +11% |
| May | 6 | 3 of 6 | +3.2% |
| Jun | 6 | 6 of 6 | +13% |
| Jul | 7 | 4 of 7 | −1.8% |
| Aug | 7 | 2 of 7 | −3.4% |
| Sep | 7 | 1 of 7 | −2.6% |
| Oct | 7 | 2 of 7 | −0.93% |
| Nov | 6 | 2 of 6 | −2.1% |
| Dec | 6 | 0 of 6 | −11% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.